Connect your AI

UroGen Pharma URGN Accrued compensation and employee benefits

Accrued compensation and employee benefits at other companies

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's accrued compensation and employee benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is UroGen Pharma's accrued compensation and employee benefits?: UroGen Pharma (URGN) reported accrued compensation and employee benefits of -$3.68M in Q1 2026.
How has UroGen Pharma's accrued compensation and employee benefits changed year-over-year?: UroGen Pharma's accrued compensation and employee benefits decreased by 2.1% year-over-year, from -$3.6M to -$3.68M.